Author:
Rudin Charles M.,Balli David,Lai W. Victoria,Richards Allison L.,Nguyen Evelyn,Egger Jacklynn V.,Choudhury Noura J.,Sen Triparna,Chow Andrew,Poirier John T.,Geese William J.,Hellmann Matthew D.,Forslund Ann
Funder
Bristol-Myers Squibb
National Institutes of Health
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference33 articles.
1. Small-cell lung cancer;Rudin;Nat Rev Dis Primers,2021
2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018
3. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019
4. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161;Leal;J Clin Oncol,2020
5. KEYNOTE-604: pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC);Rudin;J Clin Oncol,2020
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献